Skip to main content

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Bio-Techne (TECH) and Simulations Plus (SLP)

Tipranks - Tipranks - Fri Jan 9, 2:24AM CST

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Jazz Pharmaceuticals (JAZZ – Research Report), Bio-Techne (TECH – Research Report) and Simulations Plus (SLP – Research Report) with bullish sentiments.

Claim 70% Off TipRanks Premium

Jazz Pharmaceuticals (JAZZ)

Truist Financial analyst Joon Lee reiterated a Buy rating on Jazz Pharmaceuticals yesterday. The company’s shares closed last Wednesday at $169.37.

According to TipRanks.com, Lee is a top 100 analyst with an average return of 33.3% and a 56.5% success rate. Lee covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Rapport Therapeutics, Inc., and Ultragenyx Pharmaceutical. ;'>

Currently, the analyst consensus on Jazz Pharmaceuticals is a Strong Buy with an average price target of $214.31, representing a 27.2% upside. In a report issued on January 6, Bank of America Securities also maintained a Buy rating on the stock with a $247.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Bio-Techne (TECH)

TD Cowen analyst Kyle Boucher maintained a Buy rating on Bio-Techne yesterday. The company’s shares closed last Wednesday at $65.05.

Boucher has an average return of 19.4% when recommending Bio-Techne. ;'>

According to TipRanks.com, Boucher is ranked #5040 out of 10401 analysts.

Currently, the analyst consensus on Bio-Techne is a Moderate Buy with an average price target of $66.14, implying a 1.5% upside from current levels. In a report issued on January 5, Citi also maintained a Buy rating on the stock.

Simulations Plus (SLP)

Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Simulations Plus today. The company’s shares closed last Wednesday at $18.99.

According to TipRanks.com, Hewitt is a 2-star analyst with an average return of 0.0% and a 43.9% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Park Dental Partners, Inc., and Clover Health Investments. ;'>

Simulations Plus has an analyst consensus of Moderate Buy, with a price target consensus of $20.50.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).